title: Impact of ribotype 027 on Clostridium difficile infection in a geriatric department.
abstract: The purposes of this study were to describe the epidemiology (2001-2009) of Clostridium difficile infections (CDI) in a geriatric department and to compare the clinical data of patients infected with a 027 or non-027 strain. We retrospectively identified all geriatric patients with CDI and analysed the clinical and microbiological data of 133 patients for whom a ribotype was available between March 2003 and December 2009. The incidence of CDI in our geriatric department increased from 0.2 per 100 admissions in 2001 to 8.1 in 2004 and decreased to 1.3 in 2008 before a new rise to 2.1 in 2009. The percentage of ribotype 027 decreased from 2007 but it remained the most prevalent ribotype during the years 2007-2009, with a greater dispersion of ribotypes. The mean age of the patients was 84 years and the median Charlson index was 6.0. Previous use of fluoroquinolones was a significant risk factor for developing a CDI with an 027 strain (p = 0.001). Cure was significantly lower in the 027 group (p = 0.003). The total attributable mortality was 24.1 %. A multiparametric model showed that attributable mortality was influenced by the ribotype 027 (p = 0.037), the severity of clinical symptoms (p = 0.001) and the type of treatment (p = 0.002). Oral vancomycin had a protective effect against mortality. Attention should be paid to elderly patients developing a CDI, especially after the administration of fluoroquinolones. Oral vancomycin could be recommended as the first-line agent not only to protect against recurrence or severe CDI, but to diminish the attributable mortality risk.
authors.affiliation: Department of Microbiology, Centre Hospitalier Universitaire Brugmann, 4 Place Van Gehuchten, 1020 Brussels, Belgium. georges.mascart@chu-brugmann.be
authors.forename: G
authors.initials: G
authors.lastname: Mascart
authors.forename: M
authors.initials: M
authors.lastname: Delmée
authors.forename: J
authors.initials: J
authors.lastname: Van Broeck
authors.forename: E
authors.initials: E
authors.lastname: Cytryn
authors.forename: R
authors.initials: R
authors.lastname: Karmali
authors.forename: S
authors.initials: S
authors.lastname: Cherifi
mesh_terms: D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016360:Clostridioides difficile / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification*; D003015:Clostridium Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000401:mortality; D024841:Fluoroquinolones / Q000627:therapeutic use*; D006299:Health Services for the Aged; D006801:Humans; D012189:Retrospective Studies; D021521:Ribotyping; D012307:Risk Factors; D016896:Treatment Outcome; D014640:Vancomycin / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D014640:Vancomycin
references.citation: Euro Surveill. 2008 Jul 31;13(31):
references.pmid: 18761903
references.citation: CMAJ. 2004 Aug 31;171(5):466-72
references.pmid: 15337727
references.citation: Clin Infect Dis. 2005 Jun 1;40(11):1591-7
references.pmid: 15889355
references.citation: Infect Control Hosp Epidemiol. 2002 Nov;23(11):696-703
references.pmid: 12452300
references.citation: CMAJ. 2005 Oct 25;173(9):1037-42
references.pmid: 16179431
references.citation: Int J Antimicrob Agents. 2007 Oct;30(4):309-14
references.pmid: 17644347
references.citation: Euro Surveill. 2006 May 04;11(5):E060504.1
references.pmid: 16816455
references.citation: J Clin Microbiol. 2000 Jul;38(7):2484-7
references.pmid: 10878030
references.citation: Infect Control Hosp Epidemiol. 2006 Nov;27(11):1200-5
references.pmid: 17080377
references.citation: Infect Control Hosp Epidemiol. 2010 May;31(5):431-55
references.pmid: 20307191
references.citation: N Engl J Med. 2005 Dec 8;353(23):2433-41
references.pmid: 16322603
references.citation: Int J Antimicrob Agents. 2009 Mar;33 Suppl 1:S24-8
references.pmid: 19303565
references.citation: Arch Surg. 2007 Jul;142(7):624-31; discussion 631
references.pmid: 17638799
references.citation: J Antimicrob Chemother. 2010 Nov;65(11):2464-71
references.pmid: 20823105
references.citation: Clin Lab. 2008;54(1-2):9-13
references.pmid: 18510038
references.citation: Euro Surveill. 2005 Oct 20;10(10):E051020.4
references.pmid: 16790888
references.citation: Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18
references.pmid: 16965399
references.citation: J Am Geriatr Soc. 2010 Aug;58(8):1556-64
references.pmid: 20646106
references.citation: Euro Surveill. 2012 May 03;17(18):
references.pmid: 22587957
references.citation: N Engl J Med. 2005 Dec 8;353(23):2442-9
references.pmid: 16322602
references.citation: Lancet. 2005 Sep 24-30;366(9491):1079-84
references.pmid: 16182895
references.citation: J Chronic Dis. 1987;40(5):373-83
references.pmid: 3558716
references.citation: Clin Infect Dis. 2007 Aug 1;45(3):302-7
references.pmid: 17599306
references.citation: Clin Infect Dis. 2007 Jan 15;44(2):238-44
references.pmid: 17173224